These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31136997)

  • 1. Fatty liver disease in persons with HIV infection.
    Seth A; Sherman KE
    Top Antivir Med; 2019 May; 27(2):75-82. PubMed ID: 31136997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.
    Verna EC
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):211-223. PubMed ID: 28404136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
    Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
    AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.
    Han AL
    BMC Endocr Disord; 2021 May; 21(1):91. PubMed ID: 33933056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases.
    Chang Y; Cho J; Cho YK; Cho A; Hong YS; Zhao D; Ahn J; Sohn CI; Shin H; Guallar E; Ryu S
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):205-215.e7. PubMed ID: 31085337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.
    Lonardo A; Ballestri S; Guaraldi G; Nascimbeni F; Romagnoli D; Zona S; Targher G
    World J Gastroenterol; 2016 Nov; 22(44):9674-9693. PubMed ID: 27956792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV.
    Kaplan A; Simon TG; Henson JB; Wang T; Zheng H; Osganian SA; Rosenblatt R; Lake J; Corey KE
    J Acquir Immune Defic Syndr; 2020 Aug; 84(4):400-404. PubMed ID: 32235172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection.
    Maurice JB; Patel A; Scott AJ; Patel K; Thursz M; Lemoine M
    AIDS; 2017 Jul; 31(11):1621-1632. PubMed ID: 28398960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Alcoholic Fatty Liver Disease in Patients with HIV Infection.
    Papagianni M; Tziomalos K
    AIDS Rev; 2018; 20(3):171-173. PubMed ID: 30264828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing nonalcoholic fatty liver disease in patients living with HIV.
    Tafesh ZH; Verna EC
    Curr Opin Infect Dis; 2017 Feb; 30(1):12-20. PubMed ID: 27941355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of nonalcoholic fatty liver disease on clinical outcomes in patients with COVID-19 among persons living with HIV: A multicenter research network study.
    Krishnan A; Woreta TA; Sims OT; Hamilton JP; Potter JJ; Alqahtani SA
    J Infect Public Health; 2023 May; 16(5):673-679. PubMed ID: 36931143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
    Luo J; Xu L; Li J; Zhao S
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):193-9. PubMed ID: 25563143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coffee Intake and Liver Steatosis: A Population Study in a Mediterranean Area.
    Veronese N; Notarnicola M; Cisternino AM; Reddavide R; Inguaggiato R; Guerra V; Rotolo O; Zinzi I; Leandro G; Correale M; Tutino V; Misciagna G; Osella AR; Bonfiglio C; Giannelli G; Caruso MG;
    Nutrients; 2018 Jan; 10(1):. PubMed ID: 29342916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcoholic fatty liver disease elevates estimated coronary heart disease risk to levels comparable with those of nonalcoholic fatty liver disease in the Korean population: a cross-sectional study.
    Kim HJ; Kim JH; Choe WH; Kwon SY; Lee CH
    Clin Mol Hepatol; 2014 Jun; 20(2):154-61. PubMed ID: 25032181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH).
    Senussi NH; McCarthy DM
    Ann Hepatol; 2021; 24():100526. PubMed ID: 34509272
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes.
    Käräjämäki AJ; Bloigu R; Kauma H; Kesäniemi YA; Koivurova OP; Perkiömäki J; Huikuri H; Ukkola O
    Metabolism; 2017 Jan; 66():55-63. PubMed ID: 27423871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.